1. Home
  2. HGTY vs EVO Comparison

HGTY vs EVO Comparison

Compare HGTY & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hagerty Inc.

HGTY

Hagerty Inc.

N/A

Current Price

$13.16

Market Cap

1.1B

Sector

Finance

ML Signal

N/A

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$1.89

Market Cap

778.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HGTY
EVO
Founded
1984
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
778.3M
IPO Year
2021
2007

Fundamental Metrics

Financial Performance
Metric
HGTY
EVO
Price
$13.16
$1.89
Analyst Decision
Buy
Strong Buy
Analyst Count
6
1
Target Price
$13.67
$7.00
AVG Volume (30 Days)
145.0K
45.3K
Earning Date
05-06-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,456,389,000.00
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
$17.74
$10.05
P/E Ratio
N/A
N/A
Revenue Growth
21.36
N/A
52 Week Low
$9.36
$1.89
52 Week High
$14.00
$4.27

Technical Indicators

Market Signals
Indicator
HGTY
EVO
Relative Strength Index (RSI) 62.77 35.95
Support Level $13.08 N/A
Resistance Level $13.94 $2.20
Average True Range (ATR) 0.41 0.05
MACD 0.01 0.01
Stochastic Oscillator 51.54 0.00

Price Performance

Historical Comparison
HGTY
EVO

About HGTY Hagerty Inc.

Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically, it serves Europe, Canada, and the United States.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: